Identification of drug combinations to reduce the risk of pioglitazone-related bladder cancer using the FDA adverse event reporting system database
Through comprehensive data mining, 14 PTs associated with BC were identified, indicating that specific medication combinations might mitigate the risk of PLZ-related BC. Our findings offer valuable insights for guiding decisions on PLZ combination therapies.
Authors
- Hai-Yan Chen
- Qian Zhang (ORCID: https://orcid.org/0000-0001-5715-4877)
- Xiaoyan Qiu (ORCID: https://orcid.org/0000-0002-6806-6749)
- Hui Zhao (ORCID: https://orcid.org/0000-0003-1030-4991)
- Zheng Xiang (ORCID: https://orcid.org/0009-0004-1772-6534)
- M. Yan (ORCID: https://orcid.org/0000-0003-1595-0503)
- Junjie Yang (ORCID: https://orcid.org/0009-0004-8327-7482)
Institutions
- Fudan University (CN)
- Wenzhou Medical University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1080/14740338.2025.2492744
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shanghai Hospital Development Center
- Zhejiang Pharmaceutical Association